Skip to Content

Ergoloid Tablets

Generic Name: ergoloid mesylates
Dosage Form: tablet


Rx only

Ergoloid Tablets Description

Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:

Dihydroergocornine -CH(CH3)2
Dihydroergocristine -CH2C6H5
Dihydro-α-ergocryptine -CH2CH(CH3)2
Dihydro-β-ergocryptine -CH(CH3)CH2CH3

C31H41N5O5 • CH4O3S (dihydroergocornine mesylate)

C35H41N5O5 • CH4O3S (dihydroergocristine mesylate)

C32H43N5O5 • CH4O3S (dihydro-α-ergocryptine mesylate)

C32H43N5O5 • CH4O3S (dihydro-β-ergocryptine mesylate)

exists as a mixture of alpha and beta isomers in a ratio of 2:1
1 mg
Dihydroergocristine mesylate 0.333 mg
Dihydroergocornine mesylate 0.333 mg
Dihydroergocryptine mesylate* 0.333 mg

Inactive ingredients for oral tablets are: butylated hydroxyanisol, hydrogenated vegetable oil, lactose, mannitol, polyvinyl pyrrollidone, corn starch, stearic acid and talc.

Ergoloid Tablets - Clinical Pharmacology

There is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.

Pharmacokinetic Properties

Pharmacokinetic studies have been performed in normal volunteers with the help of radiolabelled drug as well as employing a specific radioimmunoassay technique. From the urinary excretion quotient of orally and intravenously administered tritium-labelled ergoloid mesylates the absorption of ergoloid was calculated to be 25%. Following oral administration, peak levels of 0.5 ngEq/mL/mg were achieved within 1.5–3 hr. Bioavailability studies with the specific radioimmunoassay confirm that ergoloid is rapidly absorbed from the gastrointestinal tract, with mean peak levels of 0.05–0.13 ng/mL/mg (with extremes of 0.03 and 0.18 ng/mL/mg) achieved within 0.6–1.3 hr (with extremes of 0.4 and 2.8 hr). The finding of lower peak levels of ergoloid compared to the total drug-metabolite composite is consistent with a considerable first pass liver metabolism, with less than 50% of the therapeutic moiety reaching the systemic circulation. The elimination of radioactivity, representing ergoloid plus metabolites bearing the radiolabel, was biphasic with half-lives of 4 and 13 hr. The mean half-life of unchanged ergoloid in plasma is about 2.6–5.1 hr; after 3 half-lives ergoloid plasma levels are less than 10% of radioactivity levels, and by 24 hr no ergoloid is detectable.

Bioequivalence studies were performed comparing ergoloid mesylates oral tablets (administered orally) with ergoloid mesylates sublingual tablets (administered sublingually). The oral tablet and sublingual tablet were shown to be bioequivalent.


A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia).

Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS).

The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time.

The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.


Ergoloid mesylates preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Ergoloid mesylates preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.


Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing ergoloid mesylates preparations.

Adverse Reactions

Ergoloid mesylates preparations have not been found to produce serious side effects. Transient nausea and gastric disturbances have been reported. Ergoloid mesylates preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.

Ergoloid Tablets Dosage and Administration

1 mg three times a day.

Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.

How is Ergoloid Tablets Supplied

Ergoloid mesylates tablets, USP (oral) 1 mg are white, round, unscored, debossed MP 20

Bottles of 100                    NDC 42291-267-01

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature]


Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 01/09 (Rev. 1)
AV 08/14 (P)




Ergoloid Mesylates Tablets USP (ORAL)

1 mg

100 Tablets       Rx Only

Each oral tablet contains 1 mg of ergoloid mesylates containing, as the mesylate salts (see insert),
Dihydroergocomine .......................... 0.333 mg
Dihydroergocristine ........................... 0.333 mg
Dihydro-alpha-ergocryptine ............... 0.222 mg
Dihydro-beta-ergocryptine ................ 0.111 mg

See package insert for full prescribing information.

See package insert for full prescribing information.

Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature]


Tablet debossed: MP 20

Keep out of the reach of children.

Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 1/08Ch
AV 08/14 (P)

N3   42291 26701   5

dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydro-.beta.-ergocryptine mesylate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:42291-267(NDC:53489-281)
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Dihydroergocornine Mesylate (Dihydroergocornine) Dihydroergocornine Mesylate 0.333 mg
Dihydroergocristine Mesylate (Dihydroergocristine) Dihydroergocristine Mesylate 0.333 mg
Dihydro-.alpha.-ergocryptine mesylate (Dihydro-.alpha.-ergocryptine) Dihydro-.alpha.-ergocryptine mesylate 0.222 mg
Dihydro-.beta.-ergocryptine mesylate (Epicriptine) Dihydro-.beta.-ergocryptine mesylate 0.111 mg
Inactive Ingredients
Ingredient Name Strength
butylated hydroxyanisole  
starch, corn  
hydrogenated cottonseed oil  
povidone k90  
stearic acid  
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 8mm
Flavor Imprint Code MP;20
# Item Code Package Description
1 NDC:42291-267-01 100 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA081113 08/22/2014
Labeler - AvKARE, Inc. (796560394)
Revised: 08/2014
AvKARE, Inc.